A short review on antibody therapy for COVID-19

被引：45

作者：

Kumar, G. Venkat ^{[1
]}

Jeyanthi, V ^{[2
]}

Ramakrishnan, S. ^{[3
]}

机构：

[1] Ponnaiyah Ramajayam Inst Sci & Technol, Dept Biotechnol, Thanjavur 613403, Tamil Nadu, India

[2] SRM Arts & Sci Coll, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India

[3] NCI, Struct Biophys Lab, Ctr Canc Res, Frederick, MD 21702 USA

来源：

NEW MICROBES AND NEW INFECTIONS | 2020年 / 35卷

关键词：

Convalescent plasma therapy; monoclonal antibody therapy; receptor binding domain; SARS-CoV-2; spike protein; CONVALESCENT PLASMA; SARS CORONAVIRUS; SPIKE; PROTEIN; BINDING;

D O I：

10.1016/j.nmni.2020.100682

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy. (C) 2020 The Authors. Published by Elsevier Ltd.

引用

页数：4

共 35 条

[1] The proximal origin of SARS-CoV-2 [J].

Andersen, Kristian G. ;

Rambaut, Andrew ;

Lipkin, W. Ian ;

Holmes, Edward C. ;

Garry, Robert F. .

NATURE MEDICINE, 2020, 26 (04) :450-452

[2] Convalescent plasma therapy for persistent hepatitis E virus infection [J].

Ankcorn, Michael ;

Gallacher, Jennifer ;

Ijaz, Samreen ;

Taha, Yusri ;

Harvala, Heli ;

Maclennan, Sheila ;

Thomson, Emma C. ;

Davis, Chris ;

Singer, Joshua B. ;

Filipe, Ana da Silva ;

Smollett, Katherine ;

Niebel, Marc ;

Semple, Malcolm G. ;

Tedder, Richard S. ;

McPherson, Stuart .

JOURNAL OF HEPATOLOGY, 2019, 71 (02) :434-438

[3]

[Anonymous], 2020, J ZHEJIANG U MED SCI

[4] Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians [J].

Arabi, Yaseen M. ;

Al-Enezi, Farhan ;

Longuere, Kajsa-Stina ;

Balkhy, Hanan H. ;

Al-Sultan, Mohamed ;

Al-Omari, Awad ;

Al-Hameed, Fahad M. ;

Carson, Gail ;

Shindo, Nahoko ;

Fowler, Robert .

BMC ANESTHESIOLOGY, 2016, 16

[5] The convalescent sera option for containing COVID-19 [J].

Casadevall, Arturo ;

Pirofski, Liise-Anne .

JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) :1545-1548

[6] Convalescent plasma as a potential therapy for COVID-19 [J].

Chen, Long ;

Xiong, Jing ;

Bao, Lei ;

Shi, Yuan .

LANCET INFECTIOUS DISEASES, 2020, 20 (04) :398-400

[7]

Chen Z, 2020, Multiscale Modeling Simulation

[8] Use of convalescent plasma therapy in SARS patients in Hong Kong [J].

Cheng, Y ;

Wong, R ;

Soo, YOY ;

Wong, WS ;

Lee, CK ;

Ng, MHL ;

Chan, P ;

Wong, KC ;

Leung, CB ;

Cheng, G .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (01) :44-46

[9] Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study [J].

Chowell, Gerardo ;

Abdirizak, Fatima ;

Lee, Sunmi ;

Lee, Jonggul ;

Jung, Eunok ;

Nishiura, Hiroshi ;

Viboud, Cecile .

BMC MEDICINE, 2015, 13

[10] Toxicokinetics of hydroxychloroquine following a massive overdose [J].

de Olano, Jonathan ;

Howland, Mary Ann ;

Su, Mark K. ;

Hoffman, Robert S. ;

Biary, Rana .

AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2019, 37 (12) :2264.e5-2264.e8

← 1 2 3 4 →